Assessing pulmonary circulation in severe bronchopulmonary dysplasia using functional echocardiography

Arvind Sehgal1,2 | Douglas Blank1,2 | Calum T. Roberts1,2 | Samuel Menahem3 | Stuart B. Hooper4,5

Abstract
Pulmonary hypertension (PH) is common in infants with severe bronchopulmonary dysplasia (BPD) and increases the risk of death. The objectives of this preliminary study were to compare responses of pulmonary circulation parameters to 100% oxygen (O2) and inhaled nitric oxide (iNO) in infants with BPD and PH using echocardiography. Responses between fetal growth restriction (FGR) and appropriate for gestational age infants were compared. Ten infants <28 weeks GA at birth were assessed at ≥36 weeks corrected gestation. Baseline echocardiography1 was performed which was repeated (echocardiography2) after 30 minutes of O2. After a gap of 2–3 hours, iNO was administered for 15 minutes and echocardiography3 was performed, followed by iNO weaning. The gestation and birthweight of the cohort were 25.9 ± 1.6 weeks and 612 ± 175 g. Assessments were performed at 38.7 ± 1.4 weeks corrected gestational age. Baseline time to peak velocity: right ventricular ejection time (TPV/RVETc) increased from 0.24 ± 0.02 to 0.27 ± 0.02 (O2, \( p = .01 \)) and 0.31 ± 0.03 (iNO, \( p < .001 \)), indicating a decrease in pulmonary vascular resistance [PVR]. Baseline tricuspid annular plane systolic excursion (TAPSE) increased from 8.1 ± 0.6 mm to 9.3 ± 0.7 mm (O2, \( p = .01 \)) and 10.5 ± 1.1 mm (iNO, \( p = .0004 \)), indicating improved ventricular systolic performance. Percentage change for all parameters was greater with iNO. Significant correlations between cardiac performance and PVR were noted. FGR infants noted higher baseline PVR (TPV/RVETc, 0.21 ± 0.02 vs. 0.25 ± 0.01, \( p = .002 \)), lower ventricular performance (TAPSE, 7 ± 1.2 mm vs. 8.6 ± 6 mm, \( p = .003 \)), and lower percentage change with O2 and iNO. A reactive component of pulmonary circulation provides real-time physiological information, which could rationalize treatment decisions.

Keywords
bronchopulmonary dysplasia, fetal growth restriction, nitric oxide, pulmonary hypertension
1 | INTRODUCTION

Bronchopulmonary dysplasia (BPD) remains the most common respiratory sequelae of prematurity. The occurrence of pulmonary hypertension (PH) in this cohort influences survival and significantly increases mortality compared to equally preterm infants with BPD but without PH (An et al., 2010; Bhat et al., 2012; Del Merro et al., 2016; Mourani & Abman, 2013). Hypoxia-mediated pulmonary vasoconstriction plays an important role in the causation of PH in this cohort (Ajami et al., 2011; Ambalavanan & Mourani, 2014; Bhatt et al., 2001; Coalson, 2006). While this may provide the reversible component (reversed by pulmonary vasodilatation), the remodeling of pulmonary vasculature (due to chronic hypoxia) may contribute to the “fixed” or unresponsive component of PH. Among the prenatal factors, the evolving pattern of BPD also suggests an important pathogenic role for fetal growth restriction (FGR) (Bhatt et al., 2001; Coalson, 2006; Sehgal, Gwini, et al., 2019). The incidence of FGR is high (approximately 27%) among premature births (Sehgal et al., 2019b). Combined, FGR and BPD in the same patient, significantly worsen the clinical and longer-term respiratory outlook. By way of chronic hypoxia, in utero placental insufficiency affects the lung parenchyma and vasculature (Maritz et al., 2004, 2005). Data from rats and human infants noted thickened pulmonary arteries indicating the biological plausibility of FGR affecting the pulmonary circulation (Rabinovitch et al., 1979; Sehgal, Gwini, et al., 2019).

While the use of long-term pulmonary vasodilators in these cohorts is common, the assessment of pulmonary circulation and its reactivity to pulmonary vasodilators before administration may enable risk stratification. Performed with cardiac catheterization (CATH) support, it is a standard approach in many institutions (Abman et al., 2015; Douwes et al., 2016; Sharma et al., 2016). A decline in pulmonary artery (PA) pressure and pulmonary vascular resistance (PVR) indicates a reactive component to PH (Khemani et al., 2007). In a retrospective study, 13/20 (65%) BPD infants demonstrated such response (≥ 20% change in indexed PVR) (Steurer et al., 2019). From the clinical outlook perspective, a responsive circulation is associated with decreased short/long-term morbidity, contributing to the clinical outlook (Barst, 1986; Douwes et al., 2016; Frank et al., 2019; Sitbon et al., 2005). However, cardiac CATH is an invasive procedure, oftentimes requiring the the transport of critically ill patients. With wide availability of echocardiography, non-invasive screening for chronic PH is considered a standard of care in many perinatal centers (An et al., 2010; Arjaans et al., 2018; Bhat et al., 2012; Levy et al., 2020; Revanna et al., 2017). Experience in the assessment of right ventricular (RV) performance and PVR opens up possibilities of assessing the pulmonary circulation with echocardiography monitoring.

This study aimed to assess the pulmonary circulation with echocardiography monitoring, comparing hemodynamic responses for 100% oxygen (O₂) with inhaled nitric oxide (iNO), as well as between FGR and appropriate for gestational age (AGA) infants. Such assessments with echocardiographic guidance in cohorts of BPD-associated PH have not been reported earlier.

2 | METHODS

Institutional Human Research Ethics Committee approved this preliminary hypothesis-generating study (Ref: RES-19-000394L – 53603). After informed written parental consent, 10 infants’ <28 weeks’ GA and severe BPD and PH formed the cohort (severe BPD-need for positive pressure support and ≥30% O₂). Normal cardiac anatomy and pulmonary venous connections were documented. Infants were assessed at ≥36 weeks’ corrected GA. FGR was defined as birthweight <10th centile for GA and sex and with absent/reversed antenatal Doppler's (Fenton & Kim, 2013). Echocardiography1 was performed with the infant on its baseline respiratory support settings. Echocardiography2 was performed after 30 minutes of 100% O₂ administered through continuous positive airway pressure (subsequently returned to baseline). After approximately 2–3 hours, iNO was administered through continuous positive airway pressure for 15 minutes at 20 ppm (baseline respiratory support settings). iNO was subsequently weaned over 15 minutes. No pharmacologic sedation was used. The same operator using the Vivid E95 Cardiovascular Ultrasound System (GE Medical Systems, Milwaukee, WI, USA) performed assessments. Previously studied echocardiography parameters were assessed which represented assessments of PVR and RV systolic performance (Czernik et al., 2012; Evans & Archer, 1999; Hayabuchi et al., 2016; Howard et al., 2012; Jain et al., 2014; Koestenberger et al., 2011, 2016; Levy et al., 2015, 2016, 2019; Milnor et al., 1969; Musewe et al., 1990; Patel et al., 2019; Sehgal et al., 2019c, 2020; Ziino et al., 2010). The exact views and cursor position for each assessment and the component of cardiac and pulmonary function assessed has been summarized earlier in our previous publication (Sehgal, Bhatia, et al., 2019). All pulse wave Doppler measurements were calculated from the average of three consecutive cardiac cycles. Left lower pulmonary vein was used uniformly from the “crab-view.”
2.1 Statistical analysis

The data are presented as mean ± standard deviation. Baseline data from echocardiography 1 were compared with echocardiography 2 (100% O₂) and echocardiography 3 (iNO), followed by comparisons between echocardiography 2 and echocardiography 3 using Student’s two-tailed t test. Differences were considered significant if p < .05. Pearson product-moment correlation coefficient, coefficient of determination, the slope of the regression line, and the Y intercept of the regression line were used to describe the relationship between the measures of RV performance and measures of PVR.

3 RESULTS

Table 1 depicts baseline demographic and clinical information. All the infants were receiving non-invasive ventilation at the time of the study (continuous positive airway pressure). None of the infants were intubated and mechanically ventilated or were on pulmonary vasodilators at the time of the study. Significant improvement in the measures of PVR and RV systolic performance was noted with both O₂ and iNO, which were accompanied by increased pulmonary blood flow (Table 2). “Percentage change” from baseline was significantly greater with iNO (Table 3). None of the infants dropped PVR by ≥20% with O₂ (eight infants for iNO) (by TPV/RVETc criteria); the same data for PA annular velocity were one and seven, respectively. Comparing baseline data between FGR and AGA infants, PVR was higher and RV systolic performance significantly lower in the former (Table 4). RV fractional area change (measure of global contractility) was similarly reduced in FGR infants (19.3 ± 0.47% vs. 24.5 ± 1.2%, p = .0002). “Percentage change” from baseline was greater in the AGA infants and significantly higher with iNO than O₂ (Table 5). All (7/7) AGA infants noted a ≥20% change to iNO for both parameters, while this was noted 1/3 FGR infants for TPV/RVETc and none for PA annular systolic velocity. One infant (AGA) had a patent ductus arteriosus; increased flow through the duct with O₂ and iNO is depicted in Figure 1. Significant correlations between the measures of RV performance and PVR as evidence of ventriculo-arterial coupling were noted (Figure 2). Six infants had measurable tricuspid regurgitation; the maximal velocity at baseline was 2.6 ± 0.4 m/s which changed to 2.4 ± 0.4 with O₂ (p = .5) and to 2.15 ± 0.4 with iNO (p = .058), respectively. While not an objective of this study, four infants (all AGA) were later administered sildenafil at the discretion of the medical team. Temporally, this coincided with success in being able to wean respiratory support.

4 DISCUSSION

Bedside echocardiography facilitated the assessment of pulmonary circulation, and both O₂ and iNO were significant pulmonary vasodilators, although the percentage change was greater with iNO. FGR status was a clear discriminator, indicating the persistence of in utero effects on vascular remodeling.

Assessment of pulmonary circulation in response to O₂/iNO facilitates risk stratification in BPD (Atz et al., 1999; Krishnan et al., 2017; Mourani et al., 2004). Using CATH, investigators have previously suggested a significant response to be a ≥20% drop in mean PA pressure and a decrease in PVR to systemic vascular resistance ratio (Barst, 1986). This has been recently revised to a drop in PA pressure of at least 10 mm Hg (Sitbon et al., 2005). Given this is the first study using echocardiography to compare pulmonary circulation reactivity between iNO versus 100% O₂, we used the echocardiography PVR indices, while recognizing CATH and echocardiography are two very different modalities. In a study on 26 BPD infants assessed by CATH, a change of ≥20% in PA pressures was noted in nine (35%) infants. This was associated with decreased subsequent mortality risk (Frank et al., 2019). However, unlike in our cohort, approximately half the cohort was already on pulmonary vasodilators. Use of ongoing pulmonary vasodilator therapy ranges from 33–46%, making true interpretation of response difficult (Frank et al., 2019; Steurer et al., 2019). iNO identifies patients who might not be recognized with O₂ (Barst et al., 2010; Gan et al., 2014;
Hill et al., 2010; Mourani et al., 2004). The dose of iNO used in pediatric cohorts has been variable (10–80 ppm). Both drugs have been generally administered for a variable period (≥10 minutes); in many cases, O2 and iNO have been administered together (Frank et al., 2019; Khemani et al., 2007; Steurer et al., 2019). In spite of limitations, these findings

**TABLE 2** Echocardiographic variables after interventions (oxygen [O2]/inhaled nitric oxide [iNO]), n = 10

| Variable | Baseline | 100% O2 | iNO 20 ppm | p (baseline vs. 100% O2) | p (baseline vs. iNO) | p (100% O2 vs. iNO) |
|----------|----------|---------|------------|--------------------------|---------------------|-------------------|
| Pulmonary vascular resistance | | | | | | |
| TPV/RVETc | 0.24 ± 0.02 | 0.27 ± 0.02 | 0.31 ± 0.03 | .01 | <.001 | .02 |
| TDI Pulmonary Artery Annular Peak Systolic Velocity [s1’] (cm/s) | 6.2 ± 0.2 | 7.1 ± 0.5 | 8.1 ± 0.8 | .003 | <.001 | .2 |
| Right ventricular contractility | | | | | | |
| TAPSE (mm) | 8.1 ± 0.6 | 9.3 ± 0.7 | 10.5 ± 1.1 | .01 | .0004 | .056 |
| TDI tricuspid peak systolic velocity [s’] (cm/s) | 7.9 ± 0.6 | 9.2 ± 0.9 | 10.3 ± 0.8 | .011 | <.001 | .046 |
| Fractional area change (%) | 23 ± 2 | 27.6 ± 2.7 | 32 ± 3.5 | .005 | <.001 | .04 |
| Pulmonary blood flow | | | | | | |
| LPA flow (VTI, cm) | 9.9 ± 0.5 | 11.9 ± 1.1 | 14 ± 2 | .002 | .0002 | .053 |
| Pulmonary venous flow (VTI, cm) | 10.8 ± 0.7 | 12.2 ± 0.9 | 13.8 ± 1.5 | .01 | .0006 | .052 |

| Abbreviations: LPA, left pulmonary artery; RVET, right ventricular ejection time; TAPSE, tricuspid annular plane systolic excursion; TDI, tissue Doppler imaging; TPV, time to peak velocity; VTI, velocity time integral. |

**TABLE 3** Comparison of % change from baseline for parameters with 100% oxygen (O2) versus inhaled nitric oxide (iNO), n = 10

| Variable | 100% O2 | iNO (20 ppm) | p |
|----------|---------|--------------|---|
| Pulmonary vascular resistance | | | |
| TPV/RVETc | 13 ± 4 | 23 ± 4 | <.001 |
| Reactive pulmonary bed* | 0 | 8 |
| Pulmonary artery annular systolic velocity [s1’] | 12 ± 6 | 22 ± 7 | .006 |
| Reactive pulmonary bed* | 1 | 7 |
| Right ventricular contractility | | | |
| TAPSE | 13 ± 2 | 22 ± 4 | <.001 |
| TDI systolic s’ velocity | 14 ± 4 | 24 ± 5 | .0001 |

| Abbreviations: TAPSE, tricuspid annular plane systolic excursion; TDI, tissue Doppler imaging, TPV/RVET, time to peak velocity/right-ventricular ejection time |

*Change by ≥20% from the baseline

**TABLE 4** Comparison of baseline PVR and RV contractility parameters between FGR and AGA cohorts

| Variable | FGR (n−3) | AGA (n = 7) | p value |
|----------|-----------|-------------|---------|
| Pulmonary vascular resistance | | | |
| TPV/RVETc | 0.21 ± 0.02 | 0.25 ± 0.01 | .002 |
| Pulmonary artery annular systolic velocity [s1’] (cm/s) | 5.7 ± 0.1 | 6.4 ± 0.15 | .0001 |
| Right ventricular contractility | | | |
| TAPSE (mm) | 7 ± 1.2 | 8.6 ± 6 | .003 |
| TDI systolic s’ velocity (cm/s) | 6.8 ± 0.7 | 8.3 ± 0.3 | .002 |

| Abbreviations: AGA, appropriate for gestational age; FGR, fetal growth restriction; TAPSE, tricuspid annular plane systolic excursion; TDI, tissue Doppler imaging; TPV/RVET, time to peak velocity/right-ventricular ejection time. |
contribute significantly to the clinical outlook and have prognostic significance (Barst, 1986; Douwes et al., 2016; Frank et al., 2019; Sitbon et al., 2005). CATH and bedside echocardiography are performed under very different physiological conditions. The former requires intubation, sedation/analgesia, and anesthesia, which could influence real-time physiological hemodynamics. It may also reflect the effects of acute changes in lung volume/gas-exchange during ventilation with anesthesia. Echocardiography assessments are performed in awake infants with no/minimal sedation and may arguably better reflect the physiological state.

### 4.1 Mechanistic linkage

Reduced vessel density, abnormal vascular architecture, and the hypoxic pulmonary vasoconstriction play important roles in PH as well as overall BPD pathophysiology. Reversibility of hypoxic pulmonary vasoconstriction is key but adverse vascular remodeling could blunt the response. Intermittent or chronic hypoxia increase PVR via vasoconstriction, reinforcing the utility of testing the pulmonary vasoconstriction in disease severity assessment, and management of BPD associated PH. The pulmonary arterial vascular smooth muscle cells and alveolar endothelium are targets for O_2 mediated response. In the main, the vasodilatory effects of iNO are mediated via cyclic GMP, by inhibiting calcium entry into the cell and activation of K+ channels.

### 4.2 Echocardiography facilitates physiological testing of the pulmonary circulation

We utilized previously studied echocardiographic parameters. While both TAPSE and TDI velocities are afterload dependant, all parameters of RV systolic performance (longitudinal [assessed by TAPSE and TDI velocity]) and global (fractional area change) noted significant changes during pulmonary circulation reactivity testing. This suggests a close inter-play/ coupling between cardiac contractility and afterload (Figure 2). TPV/RVETc and PA annular peak systolic velocity provide a reliable estimate of invasive PVR and compliance in children (Hayabuchi et al., 2016; Levy et al., 2016); the latter has also been studied in preterm infants receiving surfactant therapy (Sehgal, Bhatia, et al., 2019; Sehgal et al., 2020). Combination of the above indices has been used to characterize ventriculo-arterial coupling for risk stratification and long-term monitoring in children with PH (Levy et al., 2016, 2018, 2019). The association between elevated PVR and the RV dysfunction, and its association with sequelae in BPD infants and other clinical situations is known (Blanca et al., 2018; Levy et al., 2019; Schäfer et al., 2018; Schäfer et al., 2019).

| Variable                              | FGR 100% O_2 | AGA 100% O_2 | p   | FGR iNO | AGA iNO | p   |
|---------------------------------------|-------------|-------------|-----|---------|---------|-----|
| Pulmonary vascular resistance         |             |             |     |         |         |     |
| TPV/RVETc                             | 10.3 ± 2    | 13.6 ± 4    | 0.25| 19.3 ± 6| 25.1 ± 3| .13 |
| Pulmonary artery annular systolic      | 5.3 ± 2     | 15.1 ± 3.9  | 0.006| 11.6 ± 0.4| 25.8 ± 3.9| .0005|
| Right ventricular contractility       |             |             |     |         |         |     |
| TAPSE                                 | 11.3 ± 2.6  | 13 ± 1.7    | 0.32| 17 ± 2.1| 24.2 ± 2.4| .003|
| TDI systolic [s'] velocity             | 9.6 ± 3.8   | 16.1 ± 1.6  | 0.01| 18 ± 3  | 24.7 ± 2.7| .015|

Abbreviations: AGA, appropriate for gestational age; FGR, fetal growth restriction; TAPSE, tricuspid annular plane systolic excursion; TDI, tissue Doppler imaging; TPV/RVET, time to peak velocity/right-ventricular ejection time.
Sehgal, Gwini, et al., 2019; Sehgal et al., 2016; Yates et al., 2008). A recent study on pediatric PH patients using CATH and echocardiography noted that the Doppler Echo–derived TAPSE/ (TPV: RVET) relationship inversely correlated with invasive systolic pulmonary pressure and PVR (Levy et al., 2018). It is an important prognostic indicator, as pulmonary vascular stiffness predicts mortality in pediatric PH patients (Douwes et al., 2013; Friesen et al., 2019; Schäfer et al., 2018).

4.3 Relevant clinical constructs

Sildenafil administration in infants who demonstrated reactivity led to significant clinical improvements (weaning of respiratory support). Identification of such a subset, where reversible pulmonary vasoconstriction is a significant contributor to BPD pathophysiology, has important therapeutic constructs. Pulmonary vasodilators are in variable use for chronic PH although are not approved by the Food and Drug Administration for use in infants. Sildenafil has been used extensively off-label for the treatment of PH in neonates, infants as well as children. Clinically, such therapies may be administered for months before/after discharge. Pulmonary vasoreactivity testing prior to long-term oral pulmonary vasodilator treatment may rationalize therapy. Current guidelines do not use such assessments as a determining factor whether a patient should be placed on sildenafil (or other pulmonary vasodilators) or not. Our results note the useful biological plausibility of such a strategy, based on which a physiologic argument of such non-invasive, bedside testing could be made. Therapeutics commonly used in adult patients should not be simply extrapolated. Pediatric PH, especially in the neonatal population, has many unique clinical features due to complex maturational influences related to lung vascular development and related factors. Physiologic assessments, including cardiac CATH, echocardiography and serum biomarkers, while associated with clinical outcomes, have not been tested as sufficient endpoints for clinical trials. Bedside echocardiography, using well-studied parameters, opens up the possibilities of precision medicine and physiologic driven approach. This is well placed to potentially personalize the care of patients with pre-term lung disease, ensuring that treatment decisions are based on underlying, demonstrable pathophysiology, and not in a “one-size fits all approach.” While ductus arteriosus is mostly closed by 36 weeks corrected GA, patency in one infant provided an immediate visual portrayal of sudden hemodynamic shift.

**FIGURE 2** Correlations between RV systolic performance and pulmonary vascular resistance
4.4  Impact of fetal growth restriction

FGR infants stood out (lower baseline RV systolic performance and elevated PVR) as well as reduced vasoreactivity (percentage change). FGR infants made up a substantial part (46%) of a previous CATH assessed cohort. In another study, FGR infants were significantly more likely to have systemic or supra-systemic baseline RV pressures than AGA infants were. However, the reactivity of this sub-cohort was not reported separately in either study (Frank et al., 2019; Khemani et al., 2007). The differential response may be explained by way of muscularization of precapillary vessels, stiff arteries (elastin degradation and its replacement by collagen [100 times stiffer]), reduced endothelial cell function, and impaired eNOS signaling (Gebb & Jones, 2003; McGillick et al., 2016; Rabinovitch et al., 1979). Greater thickening and reduced PA pulsatility are noted in human FGR newborns (Sehgal, Gwini, et al., 2019). Preterm FGR infants also have increased baseline PVR on the first postnatal day (Sehgal et al., 2020). These findings align with the concept of “fetal programming” disruptions in fetal nutrition/oxygenation may have long-lasting physiological impact. Lack of reactivity may also indicate that this sub-cohort may not benefit from long-term pulmonary vasodilation strategies, but this needs prospective longitudinal analysis.

5  CONCLUSIONS

The limitation of small numbers overall and in each group is acknowledged. Infants were not followed up with subsequent echocardiography. Despite limitations, we identified key knowledge gaps that require further study. Assessment of the pulmonary circulation using echocardiography provided real-time physiological information of the reactivity in response to pulmonary vasodilators. Such assessments may facilitate physiology-focused management and pulmonary vasodilator use, providing additional important information for risk stratification and/or response to therapeutic interventions. A prospective study assessing the clinical/echocardiography impact of ongoing vasodilator therapy comparing the responsive/non-responsive cohorts is better placed to ascertain its role as a therapeutic target. Follow-up data of survivors of vasodilator therapies are needed to assess effectiveness and long-term safety.

ACKNOWLEDGMENT

We are grateful for the cooperation of mothers and babies in this cohort.

CONFLICTS OF INTERESTS

None.
bronchopulmonary dysplasia and pulmonary hypertension: a pilot study. *Pulmonary Circulation*, 9, 1–9.

Breathnach, C. R., El-Khuffash, A., James, A., McCallion, N., & Franklin, O. (2017). Serial measures of cardiac performance using tissue Doppler imaging velocity in preterm infants less than 29 weeks gestations. *Early Human Development*, 108, 33–39.

Coalson, J. J. (2006). Pathology of bronchopulmonary dysplasia. *Seminars in Perinatology*, 30, 179–184.

Czernik, C., Rhode, S., Metze, B., Schmalisch, G., & Bühler, C. (2012). Persistently elevated right ventricular index of myocardial performance in preterm infants with incipient bronchopulmonary dysplasia. *PLOS One*, 7, e38352. https://doi.org/10.1371/journal.alone.pone.0038352

Del Merro, M. J., Moledina, S., Haworth, S. G., Ivy, D., Dabbagh, M. A., Gebb, S. A., & Jones, P. L. (2003). Hypoxia and lung branching morphogenesis. *Hypoxia*, 543, 117–126.

Fenton, T. R., Archer, L. N. (1999). Doppler assessment of pulmonary arterial hypertension in children with bronchopulmonary dysplasia: consensus statement from the Pulmonary Vascular Research Institute, Pediatric and Congenital Heart Disease Task Forces. *Pulmonary Circulation*, 6, 118–125.

Douwes, J. M., Humpf, T., Bonnet, D., Beghetti, M., Ivy, D., Berger, R. M. F., Weintraub, R., Geiger, R., Marx, M., Jing, Z., Sondgaard, L., Apitz, C., Hager, A., Szatmari, A., Milanesi, O., Saji, T., Pulido, T., Moll, J., Michalak, K., ..., Berger, J.; TOPP Investigators. (2016). Acute vasodilator response in pediatric pulmonary arterial hypertension: current clinical practice from the TOPP registry. *Journal of the American College of Cardiology*, 67, 1312–1323. https://doi.org/10.1016/j.jacc.2016.01.015

Douwes, J. M., Roofthoof, M. T., Bartelds, B., Talsma, M. D., Hillege, H. L., & Berger, R. M. F. (2013). Pulsatile haemodynamic parameters are predictors of survival in paediatric pulmonary arterial hypertension. *International Journal of Cardiology*, 168, 1370–1377.

Evans, N. J., & Archer, L. N. (1999). Doppler assessment of pulmonary arterial pressure and extra pulmonary shunting in the acute phase of hyaline membrane disease. *Archives of Disease in Childhood*, 66, 6–11.

Fenton, T. R., & Kim, J. H. (2013). A systematic review and meta-analysis to revise the Fenton growth chart for preterm infants. *BMC Pediatrics*, 13, 59. https://doi.org/10.1186/1471-2431-13-59

Frank, B. S., Schäfer, M., Grenolds, A., Ivy, D. D., Abman, S. H., & Darst, J. R. (2019). Acute vasoreactivity testing during cardiac catheterization of neonates with bronchopulmonary dysplasia-associated pulmonary hypertension. *Journal of Pediatrics*, 208, 127–133.

Friesen, R. M., Schäfer, M., Ivy, D. D., Abman, S. H., Stenmark, K., Browne, L. P., Barker, A. J., Hunter, K. S., & Truong, U. (2019). Proximal pulmonary vascular stiffness as a prognostic factor in children with pulmonary arterial hypertension. *European Heart Journal of Cardiovascular Imaging*, 20, 209–217. https://doi.org/10.1093/ehjci/jey069

Gan, H. L., Zhang, J. Q., Zhou, Q. W., Feng, L., Chen, F., & Yang, Y. (2014). Patients with congenital systemic-to-pulmonary shunts and increased pulmonary vascular resistance: what predicts post-operative survival? *PLoS One*, 9, e83976. https://doi.org/10.1371/journal.pone.0083976

Gebb, S. A., & Jones, P. L. (2003). Hypoxia and lung branching morphogenesis. *Hypoxia*, 543, 117–126.

Hayabuchi, Y., Ono, A., & Kagami, S. (2016). Pulmonary annular motion velocity assessed using Doppler tissue imaging. *Circulation Journal*, 80, 168–176.

Hill, K. D., Lim, D. S., Everett, A. D., Ivy, D. D., & Moore, J. D. (2010). Assessment of pulmonary hypertension in the pediatric catheterization laboratory: current insights from the Magic registry. *Catheter Cardiovasc Intervention*, 76, 865–873. https://doi.org/10.1002/ccd.22693

Howard, L. S., Grapsa, J., Dawson, D., Bellamy, M., Chambers, J. B., Masani, N. D., Nihoyannopoulos, P., Simon, R., & Gibbs, J. (2012). Echocardiographic assessment of pulmonary hypertension: standard operating procedure. *European Respiratory Reviews*, 21, 239–248. https://doi.org/10.1183/09059180.0003912

Jain, A., Mohamed, A., El-Khuffash, A., Connelly, K. A., Dallaire, F., Jankov, R. P., McNamara, P. J., & Mertens, L. (2014). A comprehensive echocardiography protocol for assessing neonatal right ventricular dimensions and function in the transitional period: normative data and z scores. *J Am Soc Echocardiography*, 27, 1293–1304.

Khemani, E., McElhinney, D. B., Rhein, L., Andrade, O., Lacro, R. V., Thomas, K. C., & Mullen, M. P. (2007). Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. *Pediatrics*, 120, 1260–1269. https://doi.org/10.1542/peds.2007-0971

Koestenberger, M., Grangel, G., Avian, A., Gamillscheg, A., Grillitsch, M., Cvrin, G., Burmas, A., & Hansmann, G. (2016). Normal reference values and z scores of the pulmonary artery acceleration time in children and its importance for the assessment of pulmonary hypertension. *Circulation: Cardiovascular Imaging*, 10, 1–17.

Koestenberger, M., Nagel, B., Ravekes, W., Ulersberger, B., Raith, W., Avian, A., Halb, V., Cvrin, G., Fritsch, P., & Gamillscheg, A. (2011). Systolic right ventricular function in preterm and term neonates: reference values of the tricuspid annular plane systolic excursion (TAPSE) in 258 patients and calculation of Z-score values. *Neonatology*, 100, 85–92. https://doi.org/10.1159/000322006

Krishnan, U., Feinstein, J. A., Adatia, I., Austin, E. D., Mullen, M. P., Hopper, R. K., Hanna, B., Romer, L., Keller, R. L., Fineman, J., Steinhorn, R., Kinsella, J. P., Ivy, D. D., Rosenzweig, E. B., Raj, U., Humpf, T., Abman, S. H., Coulson, J., Collaco, M., & Grenolds, A. (2017). Evaluation and management of pulmonary hypertension in children with bronchopulmonary dysplasia. *Journal of Pediatrics*, 188, 24–34. https://doi.org/10.1016/j.jpeds.2017.05.029

Levy, P. T., Dionebra, B., Holland, M. R., Sekarski, T. J., Lee, C. K., Mathur, A., Cade, W. T., Cahill, A. G., & Singh, G. K. (2015). Right ventricular function in preterm and term neonates: reference values for right ventricle areas and fractional area of change. *Journal of the American Society of Echocardiography*, 28(5), 559–569. https://doi.org/10.1016/j.echo.2015.01.024

Levy, P. T., El-Khuffash, A., Woo, K. V., Hauck, A., Hamvas, A., & Singh, G. K. (2019). A novel non-invasive index to characterize right ventricle pulmonary arterial vascular coupling in children. *JACC: Cardiovascular Imaging*, 12, 761–763. https://doi.org/10.1016/j.jcmg.2018.09.022

Levy, P. T., El-Khuffash, A., Woo, K. V., & Singh, G. K. (2018). Right ventricular-pulmonary vascular interactions: an emerging role for pulmonary artery acceleration time by echocardiography in adults and children. *Journal of the American Society of Echocardiography*, 31(8), 962–964. https://doi.org/10.1016/j.echo.2018.04.004

Levy, P. T., Jain, A., Nawaytou, H., Teitel, D., Keller, R., Fineman, J., Steinhorn, R., Abman, S. H., & McNamara, P. J. (2020). Risk Assessment and Monitoring of Chronic Pulmonary Hypertension in Premature Infants. *The Journal of Pediatrics*, 217, 199–209.e4. https://doi.org/10.1016/j.jpeds.2019.10.034
Levy, P. T., Patel, M. D., Groh, G., Choudhry, S., Murphy, J., Holland, M. R., Hamvas, A., Grady, M. R., & Singh, G. K. (2016). Pulmonary artery acceleration time provides a reliable estimate of invasive pulmonary hemodynamics in children. *Journal of the American Society of Echocardiography*, 29(11), 1056–1065. https://doi.org/10.1016/j.echo.2016.08.013

Maritz, G. S., Cock, M. L., Louey, S., Suzuki, K., & Harding, R. (2005). Early developmental origins of impaired lung structure and function. *Early Human Development*, 81(9), 763–771. https://doi.org/10.1016/j.earlhumdev.2005.07.002

Maritz, G. S., Morley, C. J., & Harding, R. (2004). Fetal growth restriction has long-term effects on postnatal lung structure in sheep. *Pediatric Research*, 55, 287–295. https://doi.org/10.1203/01.PDR.000106314.99930.65

McGillick, E. V., Orgeig, S., & Morrison, J. L. (2016). Regulation of lung maturation by prolyl hydroxylase domain (PHD) inhibition in the lung of the normally grown and placentally restricted fetus in late gestation. *American Journal of Physiology: Regulatory, Integrative and Comparative Physiology*, 310, R1126–R1143.

Milnor, W. R., Conti, C. R., Lewis, K. B., & O’Rourke, M. F. (1969). Pulmonary arterial pulse wave velocity and impedance in man. *Circulation Research*, 25, 637–649. https://doi.org/10.1161/01.RES.25.6.637

Mourani, P. M., & Abman, S. H. (2013). Pulmonary vascular disease in bronchopulmonary dysplasia: pulmonary hypertension and beyond. *Current Opinion in Pediatrics*, 25, 329–337.

Mourani, P. M., Ivy, D. D., Gao, D., & Abman, S. H. (2004). Pulmonary vascular effects of inhaled nitric oxide and oxygen tension in bronchopulmonary dysplasia. *American Journal of Respiratory and Critical Care Medicine*, 170, 1006–1013. https://doi.org/10.1164/rccm.200310-1483OC

Musewe, N. N., Poppe, D., & Smallhorn, J. F. (1990). Doppler echocardiographic measurement of pulmonary artery pressure from ductal Doppler velocities in the newborn. *Journal of the American College of Cardiology*, 15, 446–456. https://doi.org/10.1016/S0735-1097(10)80076-2

Patel, M. D., Breanach, C. R., James, A. T., Choudhry, S., McNamara, P. J., Jain, A., Franklin, O., Hamvas, A., Mertens, L., Singh, G. K., El-Khuffash, A., & Levy, P. T. (2019). Echocardiographic assessment of right ventricle afterload in preterm infants: maturational patterns of pulmonary artery acceleration time over the first year of age and implications for pulmonary hypertension. *Journal of the American Society of Echocardiography*, 32, 884–894.

Rabinovitch, M., Gamble, W., Nadas, A. S., Miettinen, O., & Reid, L. (1979). Rat pulmonary circulation after chronic hypoxia: hemodynamic and structural features. *American Journal of Physiology. Heart and Circulatory Physiology*, 236, H818–H827. https://doi.org/10.1152/ajpheart.1979.236.6.H818

Revanna, G. K., Kunjuju, A., & Sehgal, A. (2017). Bronchopulmonary dysplasia associated pulmonary hypertension: making the best use of bedside echocardiography. *Progress in Pediatric Cardiology*, 46, 39–43. https://doi.org/10.1016/j.pepcard.2016.12.003

Schäfer, M., Wilson, N., Ivy, D. D., Ing, R., Abman, S., Browne, L. P., Morgan, G., Ross, M., McLennan, D., Barker, A. J., Fonseca, B., Di Maria, M., Hunter, K. S., & Truong, U. (2018). Non-invasive wave intensity analysis predicts functional worsening in children with pulmonary arterial hypertension. *American Journal of Physiology. Heart and Circulatory Physiology*, 315, H968–H977. https://doi.org/10.1152/ajpheart.00227.2018

Sehgal, A., Bhatia, R., & Roberts, C. T. (2019). Cardiorespiratory physiology following minimally invasive surfactant therapy in preterm infants. *Neonatology*, 116, 278–285. https://doi.org/10.1159/000502040

Sehgal, A., Bhatia, R., & Roberts, C. T. (2020). Cardiovascular response and sequelae after minimally invasive surfactant therapy in growth-restricted preterm infants. *Journal of Perinatology*, 40, 1178–1184.

Sehgal, A., Gwini, S. M., Menahem, S., Allison, B. J., Miller, S. L., & Polglase, G. R. (2019). Preterm growth restriction and bronchopulmonary dysplasia: the vascular hypothesis and related physiology. *Journal of Physiology*, 597, 1209–1220.

Sehgal, A., Malikwi, A., Paul, E., Tan, K., & Menahem, S. (2016). Right ventricular function in infants with Bronchopulmonary Dysplasia: Association with respiratory sequelae. *Neonatology*, 18, 289–296. https://doi.org/10.1159/000442967

Sehgal, K., Sehgal, K., Tan, K., & Sehgal, A. (2019). Impaired in-utero growth: an important risk factor for chronic lung disease [abstract]. *Pediatric Academic Society*, E-PAS2019-442.

Sharma, A., Obiagwu, C., Mezue, K., Garg, A., Mukherjee, D., Haythe, J., Shetty, V., & Einstein, A. J. (2016). Role of vasodilator testing in pulmonary hypertension. *Progress in Cardiovascular Diseases*, 58, 425–433. https://doi.org/10.1016/j.pcad.2015.09.006

Sitbon, O., Humbert, M., Jais, X., Ito, V., Hamid, A. M., Provencher, S., Garcia, G., Parent, F., Hervé, P., & Simonneau, G. (2005). Long-term response to calcium channel blockers in idiopathic pulmonary arterial hypertension. *Circulation*, 111, 3105–3111. https://doi.org/10.1161/CIRCULATIONAHA.104.488426

Steurer, M. A., Nawaytou, H., Guslits, E., Colglazier, E., Teitel, D., Finegan, J. R., & Keller, R. L. (2019). Mortality in infants with bronchopulmonary dysplasia: Data from cardiac catheterization. *Pediatric Pulmonology*, 54, 804–813. https://doi.org/10.1002/ppul.24297

Yates, A. R., Welty, S. E., Gest, A. L., & Cua, C. L. (2008). Myocardial tissue doppler changes in patients with bronchopulmonary dysplasia. *Journal of Pediatrics*, 152, 766–770. https://doi.org/10.1016/j.jpeds.2007.11.039

Ziino, A. J. A., Ivanovska, J., Belcastro, R., Kantores, C., Xu, E. Z., Ziino, E., Yates, A. R., Welty, S. E., Gest, A. L., & Cua, C. L. (2008). Myocardial tissue doppler changes in patients with bronchopulmonary dysplasia. *Journal of Pediatrics*, 152, 766–770. https://doi.org/10.1016/j.jpeds.2007.11.039

Ziino, A. J. A., Ivanovska, J., Belcastro, R., Kantores, C., Xu, E. Z., Lau, M., McNamara, P. J., Tanswell, A. K., & Jankov, R. P. (2016). Role of vasodilator testing in pulmonary hypertension. *American Journal of Physiology. Heart and Circulatory Physiology*, 58, 425–433. https://doi.org/10.1152/ajpheart.00227.2018

Ziino, A. J. A., Ivanovska, J., Belcastro, R., Kantores, C., Xu, E. Z., Lau, M., McNamara, P. J., Tanswell, A. K., & Jankov, R. P. (2016). Effects of Rho-kinase inhibition on pulmonary hypertension, lung growth, and structure in neonatal rats chronically exposed to hypoxia. *Pediatric Research*, 67, 177–182. https://doi.org/10.1203/PDR.0b013e3181c6e5a7

How to cite this article: Sehgal A, Blank D, Roberts CT, Menahem S, Hooper SB. Assessing pulmonary circulation in severe bronchopulmonary dysplasia using functional echocardiography. *Physiol Rep*. 2021;9:e14690. https://doi.org/10.14814/phy2.14690